Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

Donor-specific antibodies require preactivated immune system to harm renal transplant (CROSBI ID 229288)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Süsal, Caner ; Döhler, Bernd ; Ruhenstroth, Andrea ; Morath, Christian ; Slavcev, Antonij ; Fehr, Thomas ; Wagner, Eric ; Krüger, Bernd ; Rees, Margaret ; Balen, Sanja et al. Donor-specific antibodies require preactivated immune system to harm renal transplant // EBioMedicine, 9 (2016), 366-371. doi: 10.1016/j.ebiom.2016.06.006

Podaci o odgovornosti

Süsal, Caner ; Döhler, Bernd ; Ruhenstroth, Andrea ; Morath, Christian ; Slavcev, Antonij ; Fehr, Thomas ; Wagner, Eric ; Krüger, Bernd ; Rees, Margaret ; Balen, Sanja ; Živčić-Ćosić, Stela ; Norman, Douglas J. ; Kuypers, Dirk ; Emonds, Marie-Paule ; Pisarski, Przemyslaw ; Bösmüller, Claudia ; Weimer, Rolf ; Mytilineos, Joannis ; Scherer, Sabine ; Tran, Thuong H. ; Gombos, Petra ; Schemmer, Peter ; Zeier, Martin ; Opelz, Gerhard

engleski

Donor-specific antibodies require preactivated immune system to harm renal transplant

Background It is an unresolved issue why some kidney transplant recipients with pretransplant donor-specific HLA antibodies (DSA) show a high transplant failure rate, whereas in other patients DSA do not harm the graft. We investigated whether help from preactivated T-cells might be necessary for DSA to exert a deleterious effect. Methods The impact of pretransplant DSA and immune activation marker soluble CD30 (sCD30) on 3-year graft survival was analyzed in 385 presensitized kidney transplant recipients. Findings A deleterious influence of pretransplant DSA on graft survival was evident only in patients who were positive for the immune activation marker sCD30. In the absence of sCD30 positivity, 3-year graft survival was virtually identical in patients with or without DSA (83·1±3·9% and 84·3±2·8%, P=0·81). A strikingly lower 3-year graft survival rate of 62·1±6·4% was observed in patients who were both sCD30 and DSA positive (HR 2·92, P<0·001). Even in the presence of strong DSA with ≥5, 000 MFI, the 3-year graft survival rate was high if the recipients were sCD30 negative. Interpretation Pretransplant DSA have a significantly deleterious impact on graft survival only in the presence of high pretransplant levels of the activation marker sCD30.

Single antigen bead ; HLA antibodies ; donor-specific antibodies ; sCD30 ; kidney transplantation ; graft outcome

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

9

2016.

366-371

objavljeno

2352-3964

10.1016/j.ebiom.2016.06.006

Povezanost rada

Temeljne medicinske znanosti, Kliničke medicinske znanosti

Poveznice
Indeksiranost